{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"43","value":"231"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Cmax was the concentration of study drug in the blood after the dose is administered. It was measured post-dose and was summarized using descriptive statistics.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received intravenous infusions of ramucirumab 9 mg/kg, gemcitabine 900 mg/m2 on days 1, 8, and docetaxel 75 mg/m2 on day 8 of a 21-day cycle until disease progression or a criterion for discontinuation were met.","id":"OG000","title":"Ramucirumab + Gemcitabine + Docetaxel"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All randomized participants who received at least one dose of Ramucirumab and had evaluable PK data.","reportingStatus":"POSTED","timeFrame":"0.5 hours after the end of ramucirumab infusion on Day 1 of Cycle 1","title":"Pharmacokinetics (PK): Maximum Serum Concentration of Ramucirumab (Cmax)","type":"SECONDARY","unitOfMeasure":"microgram per milliliter (µg/mL)"}